Soriot talks up an independent AstraZeneca
This article was originally published in Scrip
Executive Summary
CEO Pascal Soriot used AstraZeneca's R&D day to talk up the company's rosy prospects as an independent company. Although the likelihood of a renewed takeover bid by Pfizer looks to be waning, he is taking no chances, and at the meeting with investors R&D leaders from across the company took to the podium to explain how bright the company's future looks.